TITLE

Fine Chemical firms Seek Overseas Acquisitions

AUTHOR(S)
Scott, Alex
PUB. DATE
September 2004
SOURCE
Chemical Week;9/26/2004, Vol. 166 Issue 32, p38
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the business plans of custom pharmaceutical intermediate companies in India. Plans of custom pharmaceutical intermediate companies to acquire U.S.- and European-based companies; Percentage of stake acquired by Hikal in pharmaceutical marketing and distribution firm Marsing & Co.; Outsourcing plans of Pfizer, Bayer Healthcare and Bayer CropScience.
ACCESSION #
14650425

 

Related Articles

  • Hikal eyes more acquisitions.  // Chemical Business;Jun2005, Vol. 19 Issue 6, p79 

    Reports on the acquisition plans of Hikal Ltd. as of June 2005. Significance of the acquisition to its financial performance; Advantages of its involvement in the pharmaceutical business; Outsourcing deal with a Japanese trading company.

  • BAYER: BETTER WITH COUGHS. Gibson, Jane // ICIS Chemical Business;10/30/2006, Vol. 1 Issue 41, p7 

    The article reports on the acquisition of the pharmaceutical business of China's Topsun Science and Technology by Bayer HealthCare. The move was done to expand Bayer HealthCare's operations in the country. Bayer will pay 1.07bn yuan for the western over-the-counter cough and cold drugs business...

  • Widening the Net. Bennett, Peter A. // Drug Discovery & Development;Sep/Oct2012, Vol. 15 Issue 8, p4 

    The author discusses the collaboration of pharmaceutical companies with academic partners to achieve a return on their investment. The author cites that several pharmaceutical companies, including Eli Lilly and Co., Pfizer Inc., Bayer Healthcare LLC, have opened innovation centers for academic...

  • Reshaping CMC Development Services. Miller, Jim // Pharmaceutical Technology;Sep2005, Vol. 29 Issue 9, p102 

    Focuses on the impact of the lack of acquisition activity in the pharmaceutical sector on chemistry, manufacturing and control development services in the U.S. Changes in the way pharmaceutical companies buy contract services; Plan of pharmaceutical firms to reduce the number of suppliers they...

  • Going global. Kovac, Matt; O'Driscoll, Cath // ICIS Chemical Business;7/31/2006, Vol. 1 Issue 30, p26 

    The article focuses on cross-border mergers and acquisitions by Indian chemical companies. In 2005, Indian companies made 103 cross-border acquisitions. This trend of overseas acquisitions is said to have been caused by India's competition with western nations in areas such as active ingredients...

  • A finequestion. Cerimele, Chris // ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p13 

    The article focuses on common concerns among outsourcers of fine chemicals, and how does merger and acquisition (M&A) activity relate to those issues. According to Contract Pharma's 2006 Annual Outsourcing Survey, the top five factors include quality, timeliness, confidentiality, good...

  • Pfizer buys Pharmacia for $60bn. McKenna, Claire // BMJ: British Medical Journal (International Edition);7/20/2002, Vol. 325 Issue 7356, p123 

    Reports that Pfizer has purchased Pharmacia, a rival pharmaceutical company. Position of Pfizer as the world's leading pharmaceutical company; Competition between Pfizer and GlaxoSmithKline; Products which will be gained by Pfizer through the merger, including the arthritis drug Celebrex.

  • Incretin mimetics vie for slice of type 2 diabetes market. Shaffer, Catherine // Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p263 

    The article reports that New York-based Pfizer's acquisition of BioRexis Pharmaceutical has made it one of the growing number of companies looking for a share of the worldwide market in diabetes. The increase of the interest of pharmaceutical companies in novel targets for injectable...

  • Pfizer acquires UK drug delivery technology firm.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p19 

    Reports that industry leading pharmaceuticals group Pfizer is set to pay $125 million to fully acquire Meridica Ltd., a drug delivery technology company based in Cambridge, England. Expected completion of the transaction in the fourth quarter of 2004; Background on Meridica.

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics